In May 2024, AYVAKIT launched as the first and only FDA-approved treatment for adults with indolent systemic mastocytosis (ISM). In 2025, we created “The Body Factory” to help patients understand how this treatment works better than over-the-counter medications to reduce their symptoms by targeting the source of ISM.